Antibody-mediated PD-L1 blockade induces durable tumor regression and long-term disease stabilization in patients with advanced cancers, including colorectal and liver cancers [33–35].MSI also serves as a marker for the assessment of PD-1 antibody treatment efficacy and predicts prognosis in patients with selected solid tumors [36–39]. This evidence concerns the gene CD274 and cancer.